Self-assembling prodrug shows promise for deep-tumor photodynamic therapy
Start here
A team led by Chen Ronglin at Longgang Central Hospital has published a study in Biomaterials describing self-assembling prodrugs for photodynamic therapy of deep-seated tumors. The design pairs controllable singlet oxygen release with modulation of nitric oxide-mediated resistance, addressing two longstanding obstacles to treating tumors that standard photodynamic therapy struggles to reach. By building both functions into a single prodrug that self-assembles, the researchers aim to improve delivery and efficacy in deeper tissue. The work is a preclinical research report; clinical testing in patients, validated efficacy in specific tumor types, and a path toward regulatory approval all remain open questions.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- MedSciLonggang Central Hospital team reports self-assembling prodrug for deep-tumor photodynamic therapy in Biomaterials
A team led by Chen Ronglin at Longgang Central Hospital has published a study in Biomaterials on self-assembling prodrugs that combine controllable singlet oxygen release with modulation of nitric oxide-mediated resistance for photodynamic therapy of deep-seated tumors.
Coverage and heat for this story
Reports so far 1·Heat now 5·Peak heat 10 (Oct 20 00:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.